GH Research is expected to report zero revenue and a consensus EPS loss of $0.31, with shares trading near $28.07 against a bullish average analyst price target of $40.00. The primary focus for investors this quarter is the company's progress toward initiating its global Phase 3 pivotal program for GH001 in treatment-resistant depression (TRD) by late 2026.
Confidence in the pipeline has grown following the FDA's lifting of a clinical hold in January and the recent publication of Phase 2b data in JAMA Psychiatry showing a 57.5% remission rate. The company remains well-funded after a $111 million secondary offering in April, providing the necessary runway to reach key clinical and regulatory milestones for its proprietary mebufotenin therapies.